Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 17, 1997

View Archived Issues

Company Profile: Inhale Therapeutic Systems

Immunological method for preventing ALL in children available for licensing

NIH seeks licensees for raf protein kinase therapeutics

Brain GABA-A receptor ligands prepared at Neurogen

Bristol-Myers Squibb develops new ET antagonists

Anticonvulsants with reduced side effects from RCT

VEGF inhibitors discovered by Zeneca

New renin inhibitor in preclinical testing at JT/Yoshitomi

Novartis claims new antiasthmatic agents

Inhibitors of viral neuraminidase from Biota

American Home Products reports compounds for atherosclerosis

Antiatherosclerotic activity of Roche's benzodiazepine derivative Ro-11-1464 described

BMS to sell Gea

Clinical results reported for Onco TCS

New guidelines for patients exposed to fenfluramine or dexfenfluramine

FACET study demonstrates improved asthma control with Pulmicort and Oxis

D-19575: new cytostatic drug without renal side effects

Anesta's Actiq denied FDA approval

Development of tolerance to OPC-31260 effects in rats after chronic treatment

Roche launches Fortovase in U.S.

P&G kicks off U.S. arm of ALIVE trial

S-Nitrosocaptopril exerts both acute and chronic hypotensive effects in rats

Roche resubmits NDA for Xenical

Results reported for Myriad's CardiaRisk

Cardioprotective activity of monoHER demonstrated in preclinical models

Celecoxib: safety and efficacy data presented at rheumatology meeting

Novartis submits BLA for Simulect in U.S.

Amylin Pharmaceuticals: Q3 1997 highlights

New antidepressant and cognition enhancer developed in Russia

Biomira and Intracel negotiate acquisition of certain Biomira assets

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance
BioWorld
It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...